New Immunosuppressive Agents for Maintenance Therapy in Organ Transplantation

No abstract is available for this paper.

• Publication year

  1997

• Venue

  BioDrugs

• Publication date

  1997-12-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2165/00063030-199708060-00007PMID 18031109
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Deoxyspergualin. Mechanism of action studies of a novel immunosuppressive drug.

  2006cited by this paper
• Deoxyspergualin. Mode of action and clinical trials.

  2006cited by this paper
• Phase I study of Brequinar sodium (NSC 368390) in patients with solid malignancies

  2004cited by this paper
• Pharmacokinetics of bredinin in renal transplant patients

  2004cited by this paper
• Multicenter phase II trial of brequinar sodium in patients with advanced squamous-cell carcinoma of the head and neck

  2004cited by this paper
• Sirolimus: a new agent for clinical renal transplantation.

  1997cited by this paper
• Murine OKT4A immunosuppression in cadaver donor renal allograft recipients: a cooperative clinical trials in transplantation pilot study. Cooperative Clinical Trials in Transplantation Research Group.

  1997cited by this paper
• A randomized, double-blind, placebo-controlled study to determine safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.

  1996cited by this paper
• A randomized, double-blind, placebo-controlled study of the safety, tolerance, and preliminary pharmacokinetics of ascending single doses of orally administered sirolimus (rapamycin) in stable renal transplant recipients.

  1996cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Hypertrophic cardiomyopathy associated with tacrolimus in paediatric transplant patients.

  1995cited by this paper
• Hyperlipidemia after liver transplantation: long-term results of the FK506/cyclosporine A US Multicenter Trial. US Multicenter Study Group.

  1995cited by this paper
• Glucose metabolism following liver transplantation and immunosuppression with cyclosporine A or FK 506.

  1995cited by this paper
• Renal sodium handling with cyclosporin A and FK506 after orthotopic liver transplantation.

  1995cited by this paper
• Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression.

  1995cited by this paper
• Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience.

  1995cited by this paper
• Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group.

  1995cited by this paper
• Comparison of FK 506- and cyclosporine-based immunosuppression: FK 506 therapy significantly reduces the incidence of acute, steroid-resistant, refractory, and chronic rejection whilst possessing a comparable safety profile. European FK 506 Multicenter Liver Study Group.

  1995cited by this paper
• FK 506: long-term study in kidney transplantation. Japanese FK 506 Study Group.

  1995cited by this paper
• Immunosuppressive mechanisms and action of deoxyspergualin in experimental and clinical studies. Japanese Collaborative Transplant Study Group of NKT-01.

  1995cited by this paper
• Intestinal transplantation: 4-year experience.

  1995cited by this paper
• Multicenter comparative study of an anti-LFA-1 adhesion molecule monoclonal antibody and antithymocyte globulin in prophylaxis of acute rejection in kidney transplantation.

  1995cited by this paper
• Sodium-losing nephropathy and distal tubular damage of transplant kidneys with FK506 administration.

  1995cited by this paper
• An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation.

  1995cited by this paper
• One thousand consecutive primary orthotopic liver transplants under FK 506: survival and adverse events.

  1995cited by this paper
• The successful use of tacrolimus (FK506) in a pancreas/kidney transplant recipient with recurrent cyclosporine-associated hemolytic uremic syndrome.

  1995cited by this paper
• Successful treatment of renal allograft rejection with a humanized antilymphocyte monoclonal antibody.

  1995cited by this paper
• Inhibition of insulin production by FK 506 is caused at the transcriptional level in pancreatic beta cell when FK BP-12 content is relatively high.

  1995cited by this paper
• Japanese multicenter studies of FK 506 in renal transplantation. Japanese FK 506 Study Group.

  1995cited by this paper
• FK 506 versus cyclosporin in the prevention of renal allograft rejection — European pilot study: six-week results

  1995cited by this paper
• Clinical use of mizoribine (Bredinin) and pharmacologic monitoring assessment in renal transplantation.

  1995cited by this paper
• FK506 in liver transplantation for chronic hepatitis B: In vitro studies on lymphocyte activation and virus replication

  1995cited by this paper
• Pharmacokinetics of tacrolimus in liver transplant patients

  1995cited by this paper
• Mizoribine as an alternative to azathioprine in triple therapy immunosuppressant regimens in cadaveric renal transplantation: two successive studies.

  1995cited by this paper
• Inhibition of dihydroorotate dehydrogenase by the immunosuppressive agent leflunomide.

  1995cited by this paper
• Weight gain and lipid profile changes in liver transplant recipients: long-term results of the American FK506 Multicenter Study.

  1995cited by this paper
• Demyelinating sensorimotor polyneuropathy after administration of FK506.

  1995cited by this paper
• A prospective randomized trial of FK506 versus cyclosporine after human pulmonary transplantation.

  1994cited by this paper
• Posttransplant diabetes mellitus--a review.

  1994cited by this paper
• Immunosuppression conversion for relief of side effects.

  1994cited by this paper
• THE EFFECT OF FK506 VERSUS CYCLOSPORINE ON GLUCOSE AND LIPID METABOLISM—A RANDOMIZED TRIAL

  1994cited by this paper
• Monotherapy with cyclosporine for chronic immunosuppression in pediatric liver transplant recipients.

  1994cited by this paper
• Tacrolimus, a New Immunosuppressant—A Review of the Literature

  1994cited by this paper
• Comparison of short and long‐term renal function in liver transplant patients receiving cyclosporin or FK 506

  1994cited by this paper
• Reversal of severe FK506 side effects by conversion to cyclosporine-based immunosuppression.

  1994cited by this paper
• FK 506: an update.

  1994cited by this paper
• Serum lipid changes in liver transplant recipients in a prospective trial of cyclosporine versus FK506.

  1994cited by this paper
• Gastrointestinal toxicity associated with FK 506 in liver transplant recipients.

  1994cited by this paper
• Acute renal failure associated with the use of ibuprofen in two liver transplant recipients on FK506.

  1994cited by this paper
• Thirty years of renal transplantation in Helsinki.

  1994cited by this paper
• Maintenance immunosuppression with prednisone and RS-61443 alone following liver transplantation.

  1993cited by this paper
• New immunosuppressive agents.

  1993cited by this paper
• EPSTEIN‐BARR VIRUS SEROLOGY AND EPSTEIN‐BARR VIRUS‐ASSOCIATED LYMPHOPROLIFERATIVE DISORDERS IN PEDIATRIC LIVER TRANSPLANT RECIPIENTS

  1993cited by this paper
• Steroid withdrawal from long-term immunosuppression in liver allograft recipients.

  1993cited by this paper
• FK506 (tacrolimus), a novel immunosuppressant in organ transplantation: clinical, biomedical, and analytical aspects.

  1993cited by this paper
• Deoxyspergualin: clinical trials in renal graft rejection. Japan Collaborative Transplant Study of Deoxyspergualin.

  1993cited by this paper
• Prophylactic use of the anti-IL-2 receptor monoclonal antibody LO-Tact-1 in cadaveric renal transplantation: results of a randomized study.

  1993cited by this paper
• The Development of Brequinar as an Immunosuppressive Drug for Transplantation

  1993cited by this paper
• THE USE OF MYCOPHENOLATE MOFETIL (RS‐61443) IN HUMAN HEART TRANSPLANT RECIPIENTS

  1993cited by this paper
• Historical development of brequinar sodium as a new immunosuppressive drug for transplantation.

  1993cited by this paper
• New Immunosuppressive Drugs: Mechanistic Insights and Potential Therapeutic Advances

  1993cited by this paper
• Prevention of vascularized allograft and xenograft rejection in rodents by brequinar sodium.

  1993cited by this paper
• Tacrolimus. A review of its pharmacology, and therapeutic potential in hepatic and renal transplantation.

  1993cited by this paper
• Effects of immunosuppressive therapy on the rat aortic allograft model.

  1993cited by this paper
• Immunosuppressive and other Effects of Mycophenolic Acid and an Ester Prodrug, Mycophenolate Mofetil

  1993cited by this paper
• Morphological characteristics of renal allografts showing renal dysfunction under FK 506 therapy: is graft biopsy available to reveal the morphological findings corresponding with FK 506 nephropathy? Japanese FK 506 Study Group.

  1993cited by this paper
• FK‐506–A Novel Immunosuppressant

  1993cited by this paper
• RS-61443 for treatment-resistant human liver rejection.

  1993cited by this paper
• Characterization of human type I and type II IMP dehydrogenases.

  1993cited by this paper
• Specific and sensitive measurement of FK506 and its metabolites in blood and urine of liver-graft recipients.

  1992cited by this paper
• Rapamycin selectively inhibits interleukin-2 activation of p70 S6 kinase

  1992cited by this paper
• RS‐61443 (Mycophenolate Mofetil) A Multicenter Study for Refractory Kidney Transplant Rejection

  1992cited by this paper
• The immunosuppressive macrolides FK-506 and rapamycin.

  1991cited by this paper
• Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts.

  1991cited by this paper
• Adverse effects associated with the use of FK 506.

  1991cited by this paper
• Acute hemolytic anemia in liver and bone marrow transplant patients under FK 506 therapy.

  1991cited by this paper
• FK 506 conversion of renal allografts failing cyclosporine immunosuppression.

  1991cited by this paper
• The clinical trial of FK 506 as primary and rescue immunosuppression in adult cardiac transplantation.

  1991cited by this paper
• Early experience with FK 506 induction immunosuppression--suggestion for using oral FK 506.

  1991cited by this paper
• RS-61443--a new, potent immunosuppressive agent.

  1991cited by this paper
• In vivo inhibition of the pyrimidine de novo enzyme dihydroorotic acid dehydrogenase by brequinar sodium (DUP-785; NSC 368390) in mice and patients.

  1990cited by this paper
• Bioavailability Improvement of Mycophenolic Acid Through Amino Ester Derivatization

  1990cited by this paper
• LIPID ABNORMALITIES IN CYCLOSPORINE‐PREDNISONE‐TREATED RENAL TRANSPLANT RECIPIENTS

  1989cited by this paper
• Effects of cyclosporine therapy on plasma lipoprotein levels.

  1989cited by this paper
• Treatment of cyclosporin-induced haemolytic uraemic syndrome with FK506.

  1989cited by this paper
• Organospecific activation of azathioprine in mice: role of liver metabolism in mutation induction.

  1988cited by this paper
• Cyclosporine, low-density lipoprotein, and cholesterol.

  1988cited by this paper
• Cyclosporine, low-density lipoprotein, and cholesterol.

  1988cited by this paper
• Mycophenolic acid for psoriasis. A review of pharmacology, long-term efficacy, and safety.

  1987cited by this paper
• Antitumor activity of spergualin, a novel antitumor antibiotic.

  1986cited by this paper
• Scientific American Medicine

  1985cited by this paper
• Deleterious effect of prednisolone in HBsAg-positive chronic active hepatitis.

  1981cited by this paper
• A new antitumor antibiotic, spergualin: isolation and antitumor activity.

  1981cited by this paper
• Dialysis and transplantation: a mothers' group.

  1976cited by this paper
• The inhibition of nucleic acid synthesis by mycophenolic acid.

  1969cited by this paper

• Mechanism of tacrolimus in the treatment of lupus nephritis

  2024cites this paper
• Sensitivity of estimated tacrolimus population pharmacokinetic profile to assumed dose timing and absorption in real‐world data and simulated data

  2022cites this paper
• Effects of Last Dosing Time on Population Pharmacokinetic Analysis of Tacrolimus Performed using Extracted Data from Electronic Health Records

  2021cites this paper
• Sensitivity of Estimated Tacrolimus Population Pharmacokinetic Profile to Inaccurate Assumptions about Dose Timing and Absorption: An Investigation in Real-World and Simulated Data

  2021cites this paper
• Prodigiosin alkaloids: recent advancements in total synthesis and their biological potential

  2015cites this paper
• Alginate-based microencapsulation and lyophilization of human retinal pigment epithelial cell line (ARPE-19) for cell therapy

  2013cites this paper
• Molecular events associated with ciclosporin A-induced gingival overgrowth are attenuated by Smad7 overexpression in fibroblasts.

  2012cites this paper
• D282, a Non-Nucleoside Inhibitor of Influenza Virus Infection that Interferes with de novo Pyrimidine Biosynthesis

  2012cites this paper
• Pharmacokinetics of tacrolimus and mycophenolate mofetil in renal transplant recipients on a corticosteroid-free regimen.

  2012cites this paper
• Effect of tacrolimus on energy metabolism in human umbilical endothelial cells.

  2011cites this paper
• Initial liver graft function is a reliable predictor of tacrolimus trough levels during the first post‐transplant week

  2011cites this paper
• Long-term follow-up of patients with moderate aplastic anemia and pure red cell aplasia treated with daclizumab

  2010cites this paper
• Effect of tacrolimus on activity and expression of P-glycoprotein and ATP-binding cassette transporter A5 (ABCA5) proteins in hematoencephalic barrier cells.

  2008cites this paper
• Modulation of the electrophoretic mobility of the linker for activation of T cells (LAT) by the calcineurin inhibitors CsA and FK506: LAT is a potential substrate for PKC and calcineurin signaling pathways.

  2003cites this paper
• Tacrolimus: a further update of its use in the management of organ transplantation.

  2003cites this paper
• Rapamycin antagonizes cyclosporin A- and tacrolimus (FK506)-mediated augmentation of linker for activation of T cell expression in T cells.

  2003cites this paper
• Diabetogenic effect of tacrolimus in South African patients undergoing kidney transplantation1.

  2002cites this paper
• Piceatannol in combination with low doses of cyclosporine a prolongs kidney allograft survival in a stringent rat transplantation model1,2

  2002cites this paper
• Microencapsulation of islets of Langerhans: impact of cellular overgrowth

  2001cites this paper
• New immunosuppressive treatment in kidney transplantation.

  2000cites this paper
• Tacrolimus: a further update of its pharmacology and therapeutic use in the management of organ transplantation.

  2000cites this paper
• Synthesis and immunosuppressive activity of novel prodigiosin derivatives.

  2000cites this paper